Search
Opus Genetics Inc
IRDAdd to Watchlist
3.980USD
-0.080-1.97%
Close 11-13 16:00（ET）
331.14MMarket Cap
LossP/E TTM
Opus Genetics Inc (IRD) Stock Price Target & Forecast
Analyst Rating
Based on 18 analysts giving stock ratings to Opus Genetics Inc in the past month.
Buy
5 Strong Buy
13 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
13.167USD+258.76%
IRD Analyst Recommendation Trends
In the current month, IRD has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IRD average Analyst price target in the last month is 13.167.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
5
5
5
5
4
3
3
2
13
13
14
13
12
12
11
10
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18
18
19
18
16
15
14
12
IRD Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
8
16
12
1
0
37
Amgen Inc
AMGN
4
9
19
3
1
36
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Eli Lilly and Co
LLY
10
19
3
1
0
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Merck & Co Inc
MRK
7
16
8
0
0
31
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Financial Forecasting
Based on analysts' estimates, IRD EPS is projected to reach -0.091 in FY2026Q4, following reported EPS of -0.457 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.14
-0.16
-0.15
-0.09
-0.16
Actual
-0.75
-0.08
-0.46
--
--
Surprise
-429.28%
+45.91%
-206.63%
--
--
FAQs
What is Opus Genetics Inc's expected revenue for the next quarter?
Opus Genetics Inc's expected revenue is 7.73M.
What is Opus Genetics Inc's price target?
Analysts forecast that Opus Genetics Inc's price target is USD 13.17, with the highest forecast at USD 20.00 and the lowest forecast at USD 8.00.
How have Opus Genetics IncIRD's recent earnings per share performed?
The market expectation was USD -0.46, while Opus Genetics IncIRD's earnings per share (EPS) for the previous quarter was USD -0.08. EPS for the next quarter is expected at USD -0.09.
What is the analyst rating for Opus Genetics Inc?
Based on the ratings of Opus Genetics Inc's stock from 18 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.